Novo Nordisk and Aspect Biosystems Enter Strategic Partnership
Under this partnership, the two companies will develop bioprinted tissue therapeutics for diabetes and obesity.
Novo Nordisk announced on April 12, 2023 a collaboration with Aspect Biosystems to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of disease-modifying treatments for diabetes and obesity.
The partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s technology in stem cell differentiation and cell therapy development and manufacturing. Aspect is to receive $75 million in initial payments and up to $650 million in future milestone payments per product arising from the collaboration, plus tiered royalties. Novo Nordisk will receive an exclusive, worldwide license to use Aspect’s bioprinting technology to develop up to four products for the treatment of diabetes and/or obesity.
“We are thrilled to partner with Novo Nordisk to create breakthrough therapeutics that could transform the lives of millions of people around the world,” said Tamer Mohamed, CEO, Aspect Biosystems, in a company press release. “This partnership leverages Aspect’s full-stack tissue therapeutic platform, talented team and bold vision, and reinforces our strategy to create bioprinted tissue therapeutics through partnerships with global industry leaders while also advancing our internal therapeutic pipeline.”
Source: Novo Nordisk
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
